Author:
Schmidinger Manuela,Vogl Ursula M.,Bojic Marija,Lamm Wolfgang,Heinzl Harald,Haitel Andrea,Clodi Martin,Kramer Gero,Zielinski Christoph C.
Reference40 articles.
1. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res.,2004
2. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res.,2003
3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med.,2007
4. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance;McCubrey;Biochim Biophys Acta.,2007
5. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med.,2007
Cited by
174 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献